We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00139828
Recruitment Status : Completed
First Posted : August 31, 2005
Last Update Posted : August 30, 2007
Information provided by:

Study Description
Brief Summary:
In this postmarketing study, the safety of Nonafact® (human coagulation factor IX) is evaluated in previous treated and untreated patients with severe, moderate or mild haemophilia B.

Condition or disease Intervention/treatment Phase
Hemophilia B Drug: human coagulation Factor IX Phase 4

Detailed Description:
The clinical efficacy and safety of Nonafact® has been shown in two pre-authorisation studies. Marketing authorisation for the EU was granted 3 July 2001. The Post Marketing Study, which evaluates the clinical efficacy, immunogenicity and safety of Nonafact®, is set up according to CPMP/BPWG /198/95, rev. 1 (Final, London, 19 October 2000) 'Note for guidance on the clinical investigation of human plasma derived factor VIII and IX products'

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Post Marketing Study in Haemophilia B Patients Using Nonafact® 100 IU/ml Powder and Solvent for Solution for Injection(Human Coagulation Factor IX)(Human Plasma Derived Factor IX Product, Freeze Dried)
Study Start Date : May 2003
Study Completion Date : February 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
The amount of Nonafact® to be administered and the frequency of treatment is based on the SmPC and should always be determined on the basis of the clinical effectiveness in the individual patient
Drug: human coagulation Factor IX
Other Name: Nonafact

Outcome Measures

Primary Outcome Measures :
  1. Number of bleeding episodes (efficacy after administration) [ Time Frame: 24 months ]
  2. Haematological variables and clinical chemistry (safety) [ Time Frame: 24 months ]
  3. Adverse events (safety) [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Occurrence of antibodies to factor IX [ Time Frame: 24 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   6 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Haemophilia B (mild, moderate or severe), Haemophilia B Leyden or symptomatic carriers of Haemophilia B and Haemophilia B Leyden
  • Above the age of six, at the moment of inclusion
  • Tested positive for HAV and HBV antibodies, induced by infection or vaccination, and negative for HBsAg
  • Informed consent signed by the patients or his legally accepted representative

Exclusion Criteria:

  • Under the age of six, at the moment of inclusion
  • Tested negative for HAV and HBV antibodies
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00139828

Academic Medical Centre
Amsterdam, Netherlands, 1105 AZ
Kennemer Gasthuis
Haarlem, Netherlands
Leiden, Netherlands, 2333 ZA
UMC St. Radboud
Nijmegen, Netherlands, 6525 GA
Erasmus Medical Centre
Rotterdam, Netherlands, 3015 GD
Leyenburg Hospital
The Hague, Netherlands, 2545 CH
Van Creveldkliniek
Utrecht, Netherlands, 3584CX
Sponsors and Collaborators
Principal Investigator: E P Mauser-Bunschoten, MD, PdD UMC Utrecht, Van Creveldkliniek, Utrecht, The Netherlands
More Information

ClinicalTrials.gov Identifier: NCT00139828     History of Changes
Other Study ID Numbers: KB2000.03
First Posted: August 31, 2005    Key Record Dates
Last Update Posted: August 30, 2007
Last Verified: August 2007

Keywords provided by Sanquin:
haemophilia B
factor IX
Product Surveillance, Postmarketing
plasma products

Additional relevant MeSH terms:
Hemophilia A
Hemophilia B
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked